Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs

Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs

FromASCO Education


Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs

FromASCO Education

ratings:
Length:
7 minutes
Released:
Jul 18, 2018
Format:
Podcast episode

Description

Dr. Jonathan Strosberg, section chief of the Neuroendocrine Tumor Division of the Moffitt Cancer Center, discusses the recent FDA approval of Lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Released:
Jul 18, 2018
Format:
Podcast episode

Titles in the series (100)

The ASCO Education Podcast features expert conversations on the most talked-about topics in oncology today from physician burnout, medical cannabis, COVID and cancer and more…